DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2009/0253782 A1 Ratan Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

US 20090253782A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0253782 A1 Ratan et al. (43) Pub. Date: Oct. 8, 2009 (54) COMPOUNDS FOR ENHANCING ARGINASE Related U.S. Application Data ACTIVITY AND METHODS OF USE (60) Provisional application No. 60/807,661, filed on Jul. THEREOF 18, 2006. (76) Inventors: Rajiv R. Ratan, Scarsdale, NY Publication Classification (US); Marie T. Filbin, New York, (51) Int. Cl. NY (US) A63L/352 (2006.01) A6IP 25/28 (2006.01) Correspondence Address: (52) U.S. Cl. ........................................................ 514/454 Irving N. Feit Hoffmann & Baron, LLP (57) ABSTRACT 6900 Jericho Turnpike The present invention relates to a method for enhancing argi Syosset, NY 11791 (US) nase activity in a damagedor injured cell. In other aspects, the invention provides a method for treating a disorder that can be (21) Appl. No.: 12/309,500 treated by enhancing arginase activity in a human in need thereof, the method comprising administering to the human (22) PCT Filed: Jul.18, 2007 an effective amount of a compound that enhances arginase activity. Such disorders include ischemia, hypoxia, neurode (86). PCT No.: PCT/US2007/016335 generative disease or condition, stroke or trauma of the ner Vous system. In yet another aspect, the invention provides S371 (c)(1), methods for promoting regeneration of a neural cell in a (2), (4) Date: Jun. 23, 2009 human in need thereof. Patent Application Publication Oct. 8, 2009 Sheet 1 of 33 US 2009/0253782 A1 Figure 1 J. An. Chen. Soc., 1940, 62:3512 J. Chem. Soc., 1959, 2679 Phytochem istry 1968, 7:70 Phytochen istry 1972, 1:1089 Patent Application Publication Oct. 8, 2009 Sheet 2 of 33 US 2009/0253782 A1 Dehydrovariabilin CH4O4 Phytochen istry 1978, 17:417 Chrysophanol Phytochem istry 1972, 11:222 Patent Application Publication Oct. 8, 2009 Sheet 3 of 33 US 2009/0253782 A1 C17H14O4 282.3 Dehydrovariabilin C17H14O4. 282.3 OO21,0658 4'-methoxychalcone C16H14O2 238.3 OD211475 5,7-dimethoxyisoflavone C17H14O4 as 26964-35 2 Retusin 7-methyl ether C17H1405 298.3 OO24O645 oozoss 2-hydroxyxanthone C13H8O3 soos. 5,74'-trimethoxyflavone C18H16O5 Patent Application Publication Oct. 8, 2009 Sheet 4 of 33 US 2009/0253782 A1 rom color easo as to or ento a ?ia octor |tio orotator to to O 1500473 also rear to a 2 f oisoarseO 50 2 1 98 Anisindone retario is O1504044 C15H1403 is acrossmoor Teimo I as f 120-46-7 a torm to a on to eatio to 101OOOO3 Biochanin a C16H12O5 284.3 Patent Application Publication Oct. 8, 2009 Sheet 5 of 33 US 2009/0253782 A1 Patent Application Publication Oct. 8, 2009 Sheet 6 of 33 US 2009/0253782 A1 Figure 3 te RT-PCR better than control x2 activity in Tillorone primary screen AO2 O23OOOO9 x2 activity in Phenirdione primary screen . AO3 O1500477 not quite 2x data O1501139 Pramoxine in primary hydrochloride Screers x2 activity in Indoprofen primary screen Phenazopyridine x2 activity in hydrochloride primary Screen O1 50 04 73 not quite 2x data in primary Piperine SCreefs AO7 O1500B73 x2 activity in 6,3'-dimethoxyflavone primary screen AO8 O1504132 x2 activity in Anisindione primary screen AO9 O1502198. not quite 2x data in primary 5,4'-dimethoxyflavone Sctees A1 O 00211227 x2 activity in Pinosylwin primary screen OO2O1066 x2 activity in Der Tustone primary screen 1O O1401419 X x2 activity in 4,7-dimethoxyflavone primary screen O0210554 x2 activity in Daidzeir primary screen B04 O0200789 X x2 activity in 4'-methoxychalcone primary screen O02.11475 x2 activity in Tranilast primary screen B x2 activity in Biochanin a diacetate primary screen BO7 OO3OOSO1 Resveratrol 4'-methyl 7 BO8 O1504O44 Patent Application Publication Oct. 8, 2009 Sheet 7 of 33 US 2009/0253782 A1 ether primary screen x4 activity in Dertubone primary screen BO9 OO2O1650 x2 activity in Chlorpropham primary screen OO330051 x2 activity in . primary screen O0210296 x2 activity in Dehydrovariabilin primary Screen CO2 OO210658 X x2 activity in Retusin 7-methyl ether primary screen CO3 OO24. x2 activity in Xanthone primary screen CO4 OO200523 x2 activity in Pinosylwin methyl ether primary screen COS O02O1067 x2 activity in Chrysophanol primary screen CO6 OO30054 55 x2 activity in Apigenin primary screen CO7 OO020O846 not quite 2x data in primary 2-methoxyxanthone SCeeS 27 C08 O024O736 x2 activity in Apigenin triacetate primary screen C09 OO2005O2 x2 activity in Fenbendazole primary screen 10 O150.1016 x2 activity in Dibenzoylmethane primary screen C11 x2 activity in Methoxyvone primary screen O14006.66 x4 activity in Ginkgetin, k salt primary screen OO200436 x4 activity in Methyl robustone primary screen Dolotovo not quite 2x data Liquinitigenin dimethyl in primary ether SCsees oO 1 6O O x2 activity in primary screen O14O1406 Patent Application Publication Oct. 8, 2009 Sheet 8 of 33 US 2009/0253782 A1 channan x2 activity in Biochanin a primary screen 5,7- x2 activity in dimethoxyisoflavone primary screen x2 activity in For Thononetin primary screen not quite 2x data in primary 4'-methoxyflavone SCees x2 activity in Acacetin diacetate primary screen Patent Application Publication Oct. 8, 2009 Sheet 9 of 33 US 2009/0253782 A1 Figure 4 | Patent Application Publication Oct. 8, 2009 Sheet 10 of 33 US 2009/0253782 A1 Patent Application Publication Oct. 8, 2009 Sheet 11 of 33 US 2009/0253782 A1 Figure 6 GN CN u C) All O a r OE a V2 G S CO CS s St E CD Co S2 co s OV) o h CC r up 3 W-e aq opeze u Jo N Se Ae WNu e Seuf. We A3ee Patent Application Publication Oct. 8, 2009 Sheet 12 of 33 US 2009/0253782 A1 Figure 7 92 as CO E S 9 S. itg 9 S5 SR E5 2 5 9. C w Cyd upoW-eed opezeu ON Sieme WNueseufv empele Patent Application Publication Oct. 8, 2009 Sheet 13 of 33 US 2009/0253782 A1 92 s S RSN to 9 S C 3. S. E SR2 53 O) h CC r u3 W-e eq Opezleu, ON Se Ae WNu e Seufu We A3 ele Patent Application Publication Oct. 8, 2009 Sheet 14 of 33 US 2009/0253782 A1 Figure 9 O) w aE 9 9 to g it N5 2 O did O. (9 S V CP ... O 9 C V cy uoV-eled OpezieuoN SeAe VNu e Seufv empbee Patent Application Publication Oct. 8, 2009 Sheet 15 of 33 US 2009/0253782 A1 Figure 10 Overcoming MAG inhibition in vitro Post-treatment Acetaminphen Resveratol 4-methyl ether Chrysophanol (low dose) 7 11 Epicatechin pentaacetate N/A Patent Application Publication Oct. 8, 2009 Sheet 16 of 33 US 2009/0253782 A1 Figure 11 se .2 Patent Application Publication Oct. 8, 2009 Sheet 17 of 33 US 2009/0253782 A1 Figure 12 Patent Application Publication Oct. 8, 2009 Sheet 18 of 33 US 2009/0253782 A1 Figure 13 Overcoming MAG inhibition in vitro Pretreatent Post treatment 1 Acetaminphen None Chrysophanol (low dose) 5 None 6 methoxyvone S None 7 dehydrovariabilin 8 Phenethyl caffeate (CAPE) 11 Epicatech in pentaacetate Yes Patent Application Publication Oct. 8, 2009 Sheet 19 of 33 US 2009/0253782 A1 Figure 14 12) 10) Ev SO 3 e Co Daidzein 2. is on MAG s p up 40 2 methoxyvone or dadzeina AG tarcoprazero on A. MAG Lanzoprazole 20ty on fi AG Neurite outgrowth assay Patent Application Publication Oct. 8, 2009 Sheet 20 of 33 US 2009/0253782 A1 Figure 15 Arginase Actin Patent Application Publication Oct. 8, 2009 Sheet 21 of 33 US 2009/0253782 A1 Figure 16 2-hydroxyxanthoneto Irm2-hydroxy- 9H in xanther- 9- one 2-methoxyxanthone 2-methoxy- 9H xanthen- 9- one 3 3-methyl-1,2- methylcholanthrene dihydrocyclopentaijtetr aphene 4,7- 7-methoxy-2-(4- dimethoxyflavone methoxyphenyl)-4H chotel-4-One (IUPAC) 4'- (2E)-1-(4- methoxychalcone methoxyphenyl)-3- phenylprop-2-en-1-one (IUPAC), 1-(4- methoxyphenyl)-3- phenylprop-2-en-1-one (IUPAC) Patent Application Publication Oct. 8, 2009 Sheet 22 of 33 US 2009/0253782 A1 4'-methoxyflavone 2-(4-methoxyphenyl)- 4H-chromen-4-one (IUPAC), 5,4'- 5-methoxy-2-(4- dimethoxyflavone methoxyphenyl)-4H chronen-4-One (IUPAC) 5,7,4'- 5,7-dimethoxy-2-(4- trimethoxyflavone methoxyphenyl)-4H chromen-4-one (IUPAC) 5,7- 5,7-dimethoxy-3- dimethoxyisoflavon phenyl-4H-chromen-4- e one (IUPAC) 6,3'- 6-methoxy-2-(3- dimethoxyflavone methoxyphenyl)-4H chromen-4-One (IUPAC) Acacetin diacetate 2-(4-methoxyphenyl)-4- oxo-4H-chromene-5,7- diyl diacetate Patent Application Publication Oct. 8, 2009 Sheet 23 of 33 US 2009/0253782 A1 MOLENAME ar. In Anisindione 2-(4-methoxyphenyl)- 1H-indene-1,3(2H) - dione 4,5,7-trihydroxyflavone (chemical), 4H-1- benzopyran-4- one, 5,7-dihydroxy-2- (4-hydroxyphenyl)- (chemical), 5,7,4'- trihydroxy- flavone (chemical), 5,7- dihydroxy-2-(4- hydroxyphenyl) - 4H chromen- 4- one (IUPAC), 83244 (NSC), apigenin (common, vendor, MeSH, primary common), apigenine (common), apigenol (common), C. l. natural yellow 1 (common), flavone,4',5,7- trihydroxy- (chemical), NP-OOO448 (extract), pelargidenon 1449 (common), spigenin (common), versulin (common) Apigenin triacetate 2- (4-acetoxyphenyl)- 4-oxo- 4H- chronene 5,7-diyl diacetate Patent Application Publication Oct. 8, 2009 Sheet 24 of 33 US 2009/0253782 A1 Biochanin a 5,7-diydroxy-3-(4- methoxyphenyl)- 4H chromen- 4- one Biochanin a 3-(4-methoxyphenyl)-4- diacetate oxo-4H-chromene-5,7- diyl diacetate Chlorpropham isopropyl (3- chlorophenyl) Carbamate Chrysophanol 1,8-dihydroxy-3-methyl 9,10-anthraquinone Patent Application Publication Oct. 8, 2009 Sheet 25 of 33 US 2009/0253782 A1 Daidzein 4,7-dihydroxy-iso flavone (chemical), 4,7- dihydroxyisoflavone (chemical), 4H-1- benzopyran-4-one,7- hydroxy-3-(4- hydroxyphenyl)- (chemical), 7,4'- dihydroxyisoflavone (chemical), 7-hydroxy 3-(4-hydroxyphenyl)-4- benzopyrone (chemical), 7-hydroxy 3-(4-hydroxyphenyl)- 4H-1-benzopyrian-4- one (chemical), 7 hydroxy-3-(4- hydroxyphenyl)-4H chromen-4-one (IUPAC), 7-hydroxy-3- (4-hydroxyphenyl) chromen-4-one (chemical), daidzein (common, vendor, MeSH, primary common), daidzeol (common) Dehydrovariabilin 3,9-dimethoxy-6H 1)benzofuro3,2- cchromene Patent Application Publication Oct.
Recommended publications
  • Content and Composition of Isoflavonoids in Mature Or Immature

    Content and Composition of Isoflavonoids in Mature Or Immature

    394 Journal of Health Science, 47(4) 394–406 (2001) Content and Composition of tivities1) and reported to be protective against can- cer, cardiovascular diseases and osteoporosis.3–9) Isoflavonoids in Mature or Much research has been reported about the content Immature Beans and Bean of isoflavonoids in soybeans and soybean-derived processed foods.10–23) In contrast, there are few re- Sprouts Consumed in Japan ports about the isoflavonoid content in beans other than soybeans.11,12,18,23) Yumiko Nakamura,* Akiko Kaihara, Japanese people are reported to ingest Kimihiko Yoshii, Yukari Tsumura, isoflavonoids mainly through the consumption of Susumu Ishimitsu, and Yasuhide Tonogai soybeans and its derived processed foods.20) Re- cently, we estimated that the Japanese daily intake Division of Food Chemistry, National Institute of Health Sci- of isoflavonoids from soybeans and soybean-based ences, Osaka Branch, 1–1–43 Hoenzaka, Chuo-ku, Osaka 540– processed foods is 27.80 mg per day (daidzein 0006, Japan (Received January 9, 2001; Accepted April 6, 2001) 12.02 mg, glycitein 2.30 mg and genistein 13.48 mg).24) However, isoflavonoid intake from the The content of 9 types of isoflavonoids (daidzein, consumption of immature beans, sprouts and beans glycitein, genistein, formononetin, biochanin A, other than soybeans has not been elucidated. Here coumestrol, daidzin, glycitin and genistin) in 34 do- we have measured the content of isoflavonoids in mestic or imported raw beans including soybeans, 7 mature and immature beans and bean sprouts con- immature beans and 5 bean sprouts consumed in Ja- sumed in Japan, and have compared the content and pan were systematically analyzed.
  • Interpreting Sources and Endocrine Active Components of Trace Organic Contaminant Mixtures in Minnesota Lakes

    Interpreting Sources and Endocrine Active Components of Trace Organic Contaminant Mixtures in Minnesota Lakes

    INTERPRETING SOURCES AND ENDOCRINE ACTIVE COMPONENTS OF TRACE ORGANIC CONTAMINANT MIXTURES IN MINNESOTA LAKES by Meaghan E. Guyader © Copyright by Meaghan E. Guyader, 2018 All Rights Reserved A thesis submitted to the Faculty and the Board of Trustees of the Colorado School of Mines in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Civil and Environmental Engineering). Golden, Colorado Date _____________________________ Signed: _____________________________ Meaghan E. Guyader Signed: _____________________________ Dr. Christopher P. Higgins Thesis Advisor Golden, Colorado Date _____________________________ Signed: _____________________________ Dr. Terri S. Hogue Professor and Department Head Department of Civil and Environmental Engineering ii ABSTRACT On-site wastewater treatment systems (OWTSs) are a suspected source of widespread trace organic contaminant (TOrC) occurrence in Minnesota lakes. TOrCs are a diverse set of synthetic and natural chemicals regularly used as cleaning agents, personal care products, medicinal substances, herbicides and pesticides, and foods or flavorings. Wastewater streams are known to concentrate TOrC discharges to the environment, particularly accumulating these chemicals at outfalls from centralized wastewater treatment plants. Fish inhabiting these effluent dominated environments are also known to display intersex qualities. Concurrent evidence of this phenomenon, known as endocrine disruption, in Minnesota lake fish drives hypotheses that OWTSs, the primary form of wastewater treatment in shoreline residences, may contribute to TOrC occurrence and the endocrine activity in these water bodies. The causative agents specific to fish in this region remain poorly understood. The objective of this dissertation was to investigate OWTSs as sources of TOrCs in Minnesota lakes, and TOrCs as potential causative agents for endocrine disruption in resident fish.
  • Suspect and Target Screening of Natural Toxins in the Ter River Catchment Area in NE Spain and Prioritisation by Their Toxicity

    Suspect and Target Screening of Natural Toxins in the Ter River Catchment Area in NE Spain and Prioritisation by Their Toxicity

    toxins Article Suspect and Target Screening of Natural Toxins in the Ter River Catchment Area in NE Spain and Prioritisation by Their Toxicity Massimo Picardo 1 , Oscar Núñez 2,3 and Marinella Farré 1,* 1 Department of Environmental Chemistry, IDAEA-CSIC, 08034 Barcelona, Spain; [email protected] 2 Department of Chemical Engineering and Analytical Chemistry, University of Barcelona, 08034 Barcelona, Spain; [email protected] 3 Serra Húnter Professor, Generalitat de Catalunya, 08034 Barcelona, Spain * Correspondence: [email protected] Received: 5 October 2020; Accepted: 26 November 2020; Published: 28 November 2020 Abstract: This study presents the application of a suspect screening approach to screen a wide range of natural toxins, including mycotoxins, bacterial toxins, and plant toxins, in surface waters. The method is based on a generic solid-phase extraction procedure, using three sorbent phases in two cartridges that are connected in series, hence covering a wide range of polarities, followed by liquid chromatography coupled to high-resolution mass spectrometry. The acquisition was performed in the full-scan and data-dependent modes while working under positive and negative ionisation conditions. This method was applied in order to assess the natural toxins in the Ter River water reservoirs, which are used to produce drinking water for Barcelona city (Spain). The study was carried out during a period of seven months, covering the expected prior, during, and post-peak blooming periods of the natural toxins. Fifty-three (53) compounds were tentatively identified, and nine of these were confirmed and quantified. Phytotoxins were identified as the most frequent group of natural toxins in the water, particularly the alkaloids group.
  • Novel Bioactive Metabolites from a Marine Derived Bacterium Nocardia Sp. ALAA 2000 Mervat M

    Novel Bioactive Metabolites from a Marine Derived Bacterium Nocardia Sp. ALAA 2000 Mervat M

    J. Antibiot. 61(6): 379–386, 2008 THE JOURNAL OF ORIGINAL ARTICLE ANTIBIOTICS Novel Bioactive Metabolites from a Marine Derived Bacterium Nocardia sp. ALAA 2000 Mervat M. A. El-Gendy, Usama W. Hawas, Marcel Jaspars Received: November 4, 2007 / Accepted: June 10, 2008 © Japan Antibiotics Research Association Abstract Extracts of the Egyptian marine actinomycete, represent an enormous resource for the discovery of Nocardia sp. ALAA 2000, were found to be highly chemotherapeutic agents. Given the diversity of marine bioactive. It was isolated from the marine red alga organisms and habitats, marine natural products encompass Laurenica spectabilis collected off the Ras-Gharib coast of a wide variety of chemical classes such as terpenes, the Red Sea, Egypt. According to detailed identification polyketides, acetogenins, peptides and alkaloids of varying studies, the strain was classified as a member of the genus structures, representing biosynthetic schemes of stunning Nocardia. The cultivation and chemical analysis of this variety. Over the past 30 to 40 years, marine organisms species yielded four structurally related compounds have been the focus of a worldwide effort for the discovery namely, chrysophanol 8-methyl ether (1), asphodelin; 4,7Ј- of novel natural products [1]. Marine microorganisms bichrysophanol (2) and justicidin B (3), in addition to (actinobacteria) are sources of novel compounds with often a novel bioactive compound ayamycin; 1,1-dichloro-4- unique structures and potential therapeutic applications. ethyl-5-(4-nitro-phenyl)-hexan-2-one (4) which is unique The Actinomycetes are widely distributed in natural and in contain both chlorination and a rarely observed nitro manmade environments and are also well known as a rich group.
  • Insect-Induced Daidzein, Formononetin and Their Conjugates in Soybean Leaves

    Insect-Induced Daidzein, Formononetin and Their Conjugates in Soybean Leaves

    UC San Diego UC San Diego Previously Published Works Title Insect-induced daidzein, formononetin and their conjugates in soybean leaves. Permalink https://escholarship.org/uc/item/5pw0t3dx Journal Metabolites, 4(3) ISSN 2218-1989 Authors Murakami, Shinichiro Nakata, Ryu Aboshi, Takako et al. Publication Date 2014-07-04 DOI 10.3390/metabo4030532 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Metabolites 2014, 4, 532-546; doi:10.3390/metabo4030532 OPEN ACCESS metabolites ISSN 2218-1989 www.mdpi.com/journal/metabolites/ Article Insect-Induced Daidzein, Formononetin and Their Conjugates in Soybean Leaves Shinichiro Murakami 1, Ryu Nakata 1, Takako Aboshi 1, Naoko Yoshinaga 1, Masayoshi Teraishi 1, Yutaka Okumoto 1, Atsushi Ishihara 3, Hironobu Morisaka 1, Alisa Huffaker 2, Eric A Schmelz 2 and Naoki Mori 1,* 1 Graduate School of Agriculture, Kyoto University, Kitashirakawa, Sakyo, Kyoto 606-8502, Japan; E-Mails: [email protected] (S.M.); [email protected] (R.N.); [email protected] (T.A.); [email protected] (N.Y.); [email protected] (M.T.); [email protected] (Y.O.); [email protected] (H.M.) 2 Center for Medical, Agricultural, and Veterinary Entomology, Agricultural Research Service, USDA, 1600 S.W. 23RD Drive, Gainesville, FL 32606, USA; E-Mails: [email protected] (A.H.); [email protected] (E.A.S.) 3 Department of Agriculture, Tottori University, Koyama-machi 4-101, Tottori 680-8550, Japan; E-Mail: [email protected] * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +81-75-753-6307.
  • Formulation and Characterization of an Apigenin-Phospholipid Phytosome (APLC) for Improved Solubility, in Vivo Bioavailability, and Antioxidant Potential

    Formulation and Characterization of an Apigenin-Phospholipid Phytosome (APLC) for Improved Solubility, in Vivo Bioavailability, and Antioxidant Potential

    St. John Fisher College Fisher Digital Publications Pharmacy Faculty/Staff Publications Wegmans School of Pharmacy 12-8-2016 Formulation and characterization of an apigenin-phospholipid phytosome (APLC) for improved solubility, in vivo bioavailability, and antioxidant potential Darshan R. Telange Nagpur University Arun T. Patin Nagpur University Anil M. Pethe SVKM's NMIMS University Harshal Fegade Nagpur University SridharFollow this Anand and additional works at: https://fisherpub.sjfc.edu/pharmacy_facpub St. John Fisher College, [email protected] Part of the Pharmacy and Pharmaceutical Sciences Commons How has open access to Fisher Digital Publications benefitedSee next page for additionalou?y authors Publication Information Telange, Darshan R.; Patin, Arun T.; Pethe, Anil M.; Fegade, Harshal; Anand, Sridhar; and Dave, Vivek S. (2016). "Formulation and characterization of an apigenin-phospholipid phytosome (APLC) for improved solubility, in vivo bioavailability, and antioxidant potential." European Journal of Pharmaceutical Sciences 108, 36-49. Please note that the Publication Information provides general citation information and may not be appropriate for your discipline. To receive help in creating a citation based on your discipline, please visit http://libguides.sjfc.edu/citations. This document is posted at https://fisherpub.sjfc.edu/pharmacy_facpub/117 and is brought to you for free and open access by Fisher Digital Publications at St. John Fisher College. For more information, please contact [email protected]. Formulation and characterization of an apigenin-phospholipid phytosome (APLC) for improved solubility, in vivo bioavailability, and antioxidant potential Abstract The apigenin-phospholipid phytosome (APLC) was developed to improve the aqueous solubility, dissolution, in vivo bioavailability, and antioxidant activity of apigenin. The APLC synthesis was guided by a full factorial design strategy, incorporating specific formulation and process variables to deliver an optimized product.
  • Separation/Analysis of Chrysophanol by Ionic Liquid Loaded Β-Cyclodextrin Polymer Coupled with Ultraviolet Spectrophotometry

    Separation/Analysis of Chrysophanol by Ionic Liquid Loaded Β-Cyclodextrin Polymer Coupled with Ultraviolet Spectrophotometry

    nalytic A al & B y i tr o s c i h e Ping et al., Biochem Anal Biochem 2013, 2:3 m m e Biochemistry & i h s c t DOI: 10.4172/2161-1009.1000138 r o i y B ISSN: 2161-1009 Analytical Biochemistry Research Article Open Access Separation/Analysis of Chrysophanol by Ionic Liquid Loaded β-Cyclodextrin Polymer Coupled with Ultraviolet Spectrophotometry Wenhui Ping, Hongyan Xu and Xiashi Zhu* College of Chemistry and Chemical Engineering, Yangzhou University, China Abstract A novel method for separation/analysis of chrysophanol (Chry) in drugs is described. The work is based on the utilization of ionic liquid ([C4min] PF6) (IL) loaded β-cyclodextrin cross-linked polymer (IL-β-CDCP) for effective adsorption of Chry coupled with ultraviolet spectrophotometry for the analysis of Chry. The inclusion interaction of IL-β-CDCP with Chry is studied by FTIR and 13C-NMR. Under the optimum conditions, linear range, Detection Limit (DL) and the relative standard deviation are 0.10-20.0 μg mL-1, 0.02 μg mL-1, 0.45% (n=3, c=4.0 μg mL-1), respectively. This technique is successfully applied for determination of Chry in drug samples. Keywords: Chrysophanol; Ionic Liquid Loaded β-Cyclodextrin research on application of functionalized cyclodextrin for separation/ Polymer; Solid-Phase Extraction; Inclusion Interactions; Ultraviolet analysis includes: biological-based chitosan grafted β-cyclodextrin- Spectrophotometry benzoic acid [15]; Fe3O4/ cyclodextrin polymer nanocomposites- heavy metals [16]; β-cyclodextrin-ionic liquid polyurethanes-organic Introduction pollutants/ heavy metals [17]. Ionic liquid (IL) load β-cyclodextrin Chrysophanol (Chry, Figure 1), 1,8-dihydroxy-3- cross-linked polymer as SPE material seems to be lacking.
  • Focus on Formononetin: Anticancer Potential and Molecular Targets

    Focus on Formononetin: Anticancer Potential and Molecular Targets

    Review Focus on Formononetin: Anticancer Potential and Molecular Targets Samantha Kah Ling Ong 1, Muthu K. Shanmugam 1, Lu Fan 1, Sarah E. Fraser 3, Frank Arfuso 4, Kwang Seok Ahn 2,*, Gautam Sethi 1,* and Anupam Bishayee 3,* 1 Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117600, Singapore; [email protected] (S.K.L.O.); [email protected] (M.K.S.); [email protected] (L.F.) 2 Department of Science in Korean Medicine, Kyung Hee University, 24 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Korea 3 Lake Erie College of Osteopathic Medicine, Bradenton, FL 34211, USA; [email protected] 4 Stem Cell and Cancer Biology Laboratory, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, WA 6102, Australia; [email protected] * Correspondence: [email protected] (K.S.A.); [email protected] (G.S.); [email protected] or [email protected] (A.B.); Tel.: +82-2-961-2316 (K.S.A.); +65-6516-3267 (G.S.); +1-(941)-782-5950 (A.B.) Fax: +65-6873-7690 (G.S.) Received: 22 March 2019; Accepted: 28 April 2019; Published: 1 May 2019 Abstract: Formononetin, an isoflavone, is extracted from various medicinal plants and herbs, including the red clover (Trifolium pratense) and Chinese medicinal plant Astragalus membranaceus. Formononetin’s antioxidant and neuroprotective effects underscore its therapeutic use against Alzheimer’s disease. Formononetin has been under intense investigation for the past decade as strong evidence on promoting apoptosis and against proliferation suggests for its use as an anticancer agent against diverse cancers.
  • Simultaneous Determination of Daidzein, Genistein and Formononetin in Coffee by Capillary Zone Electrophoresis

    Simultaneous Determination of Daidzein, Genistein and Formononetin in Coffee by Capillary Zone Electrophoresis

    separations Article Simultaneous Determination of Daidzein, Genistein and Formononetin in Coffee by Capillary Zone Electrophoresis Feng Luan *, Li Li Tang, Xuan Xuan Chen and Hui Tao Liu College of Chemistry and Chemical Engineering, Yantai University, Yantai 264005, China; [email protected] (L.L.T.); [email protected] (X.X.C.); [email protected] (H.T.L.) * Correspondence: fl[email protected]; Tel.: +86-535-6902063 Academic Editor: Doo Soo Chung Received: 29 October 2016; Accepted: 20 December 2016; Published: 1 January 2017 Abstract: Coffee is a favorite and beverage in Western countries that is consumed daily. In the present study, capillary zone electrophoresis (CE) was applied for the separation and quantification of three isoflavones including daidzein, genistein and formononetin in coffee. Extraction of isoflavones from the coffee sample was carried out by extraction and purification process using ether after the acid hydrolysis with the antioxidant butylated hydroxy-toluene (BHT). The experimental conditions of the CE separation method were: 20 mmol/L Na2HPO4 buffer solution, 25 kV applied voltage, 3 s hydrodynamic injection at 30 mbar, and UV detection at 254 nm. The results show that the three compounds can be tested within 10 min with a linearity of 0.5–50 µg/mL for all three compounds. The limits of detection were 0.0642, 0.134, and 0.0825 µg/mL for daidzein, formononetin and genistein, respectively. The corresponding average recovery was 99.39% (Relative Standard Detection (RSD) = 1.76%), 98.71% (RSD = 2.11%) and 97.37% (RSD = 3.74%). Keywords: capillary zone electrophoresis (CE); daidzein; genistein; formononetin; acid hydrolysis 1.
  • IN SILICO ANALYSIS of FUNCTIONAL Snps of ALOX12 GENE and IDENTIFICATION of PHARMACOLOGICALLY SIGNIFICANT FLAVONOIDS AS

    IN SILICO ANALYSIS of FUNCTIONAL Snps of ALOX12 GENE and IDENTIFICATION of PHARMACOLOGICALLY SIGNIFICANT FLAVONOIDS AS

    Tulasidharan Suja Saranya et al. Int. Res. J. Pharm. 2014, 5 (6) INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 – 8407 Research Article IN SILICO ANALYSIS OF FUNCTIONAL SNPs OF ALOX12 GENE AND IDENTIFICATION OF PHARMACOLOGICALLY SIGNIFICANT FLAVONOIDS AS LIPOXYGENASE INHIBITORS Tulasidharan Suja Saranya, K.S. Silvipriya, Manakadan Asha Asokan* Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Viswa Vidyapeetham University, AIMS Health Sciences Campus, Kochi, Kerala, India *Corresponding Author Email: [email protected] Article Received on: 20/04/14 Revised on: 08/05/14 Approved for publication: 22/06/14 DOI: 10.7897/2230-8407.0506103 ABSTRACT Cancer is a disease affecting any part of the body and in comparison with normal cells there is an elevated level of lipoxygenase enzyme in different cancer cells. Thus generation of lipoxygenase enzyme inhibitors have suggested being valuable. Individual variation was identified by the functional effects of Single Nucleotide Polymorphisms (SNPs). 696 SNPs were identified from the ALOX12 gene, out of which 73 were in the coding non-synonymous region, from which 8 were found to be damaging. In silico analysis was performed to determine naturally occurring flavonoids such as isoflavones having the basic 3- phenylchromen-4-one skeleton for the pharmacological activity, like Genistein, Diadzein, Irilone, Orobol and Pseudobaptigenin. O-methylated isoflavones such as Biochanin, Calycosin, Formononetin, Glycitein, Irigenin, 5-O-Methylgenistein, Pratensein, Prunetin, ψ-Tectorigenin, Retusin and Tectorigenine were also used for the study. Other natural products like Aesculetin, a coumarin derivative; flavones such as ajoene and baicalein were also used for the comparative study of these natural compounds along with acteoside and nordihydroguaiaretic acid (antioxidants) and active inhibitors like Diethylcarbamazine, Zileuton and Azelastine as standard for the computational analysis.
  • Phytochem Referenzsubstanzen

    Phytochem Referenzsubstanzen

    High pure reference substances Phytochem Hochreine Standardsubstanzen for research and quality für Forschung und management Referenzsubstanzen Qualitätssicherung Nummer Name Synonym CAS FW Formel Literatur 01.286. ABIETIC ACID Sylvic acid [514-10-3] 302.46 C20H30O2 01.030. L-ABRINE N-a-Methyl-L-tryptophan [526-31-8] 218.26 C12H14N2O2 Merck Index 11,5 01.031. (+)-ABSCISIC ACID [21293-29-8] 264.33 C15H20O4 Merck Index 11,6 01.032. (+/-)-ABSCISIC ACID ABA; Dormin [14375-45-2] 264.33 C15H20O4 Merck Index 11,6 01.002. ABSINTHIN Absinthiin, Absynthin [1362-42-1] 496,64 C30H40O6 Merck Index 12,8 01.033. ACACETIN 5,7-Dihydroxy-4'-methoxyflavone; Linarigenin [480-44-4] 284.28 C16H12O5 Merck Index 11,9 01.287. ACACETIN Apigenin-4´methylester [480-44-4] 284.28 C16H12O5 01.034. ACACETIN-7-NEOHESPERIDOSIDE Fortunellin [20633-93-6] 610.60 C28H32O14 01.035. ACACETIN-7-RUTINOSIDE Linarin [480-36-4] 592.57 C28H32O14 Merck Index 11,5376 01.036. 2-ACETAMIDO-2-DEOXY-1,3,4,6-TETRA-O- a-D-Glucosamine pentaacetate 389.37 C16H23NO10 ACETYL-a-D-GLUCOPYRANOSE 01.037. 2-ACETAMIDO-2-DEOXY-1,3,4,6-TETRA-O- b-D-Glucosamine pentaacetate [7772-79-4] 389.37 C16H23NO10 ACETYL-b-D-GLUCOPYRANOSE> 01.038. 2-ACETAMIDO-2-DEOXY-3,4,6-TRI-O-ACETYL- Acetochloro-a-D-glucosamine [3068-34-6] 365.77 C14H20ClNO8 a-D-GLUCOPYRANOSYLCHLORIDE - 1 - High pure reference substances Phytochem Hochreine Standardsubstanzen for research and quality für Forschung und management Referenzsubstanzen Qualitätssicherung Nummer Name Synonym CAS FW Formel Literatur 01.039.
  • View PDF Version

    View PDF Version

    Organic & Biomolecular Chemistry View Article Online PAPER View Journal | View Issue Aryl ethynyl anthraquinones: a useful platform for targeting telomeric G-quadruplex structures† Cite this: Org. Biomol. Chem., 2014, 12, 3744 Claudia Percivalle,a Claudia Sissi,b Maria Laura Greco,b Caterina Musetti,b Angelica Mariani,a Anna Artese,c Giosuè Costa,c Maria Lucia Perrore,a Stefano Alcaroc and Mauro Freccero*a Received 28th January 2014, Aryl ethynyl anthraquinones have been synthesized by Sonogashira cross-coupling and evaluated as Accepted 4th April 2014 telomeric G-quadruplex ligands, by the FRET melting assay, circular dichroism, the DNA synthesis arrest DOI: 10.1039/c4ob00220b assay and molecular docking. Both the binding properties and G-quadruplex vs. duplex selectivity are www.rsc.org/obc controlled by the structures of the aryl ethynyl moieties. been demonstrated by means of immuno-fluorescence stain- Introduction 16 Creative Commons Attribution 3.0 Unported Licence. ing with an engineered structure-specific antibody and by Small molecule-mediated DNA targeting represents one of the Chromatin Immuno-Precipitation (ChIP-Seq).7 The potential most effective approaches for the development of chemothera- therapeutic opportunities offered by the targeting of these peutics. The ability of DNA to fold into highly stable secondary structures prompted the design of a large number of ligands structures could be exploited for the design of anticancer that specifically interact with the terminal tetrads, G4 loops agents interacting with nucleic